PROPHYLIX AS

Prophylix AS has entered into a definitive agreement with Rallybio, a U.S.-based drug development company, under which Rallybio acquires Prophylix's orphan drug programs, NAITgam and a follow-on therapy. NAITgam is a plasma-derived HPA-1a antibody in early clinical development for the treatment of fetal and neonatal alloimmune thrombocytopenia (FNAIT), a devastating, life-threatening disorder in fetuses and newborns.